| • |
Ensure that nothing is done or added to any tobacco product that increases its inherent risks |
| • |
Develop and produce products that potentially reduce the inherent risks of tobacco use or potentially re-duce exposure to reported toxicants within particular tobacco product categories |
| • |
Promote, as appropriate, migration to products with lower relative risks, either within or across tobacco product categories |
|
 While the RAI operating companies are united in their core values and objectives, programs and approaches in the areas of product integrity and harm reduction differ from company to company. These differences reflect the diversity of strengths, resources, and experience among the operating companies. Each operating company, through appropriate licensing arrangements, service contracts and other transactions, will have access to and the opportunity to use, as appropriate, relevant technologies, resources and “best practices” available within the RAI operating companies.
The most important example of cross-company collaboration is the use of service contracts to leverage the recognized strengths and capabilities of R.J. Reynolds’ research and development department.
|
|
|
|
|
Among RAI’s operating companies, due to the breadth and depth of its research and development infrastructure, R.J. Reynolds continues to take the lead in applying rigorous scientific techniques to tobacco product harm reduction efforts.
|
|